日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

学術論文

Investigating light sensitivity in bipolar disorder (HELIOS-BD)

MPS-Authors
/persons/resource/persons268323

Spitschan,  M       
Research Group Translational Sensory and Circadian Neuroscience, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

https://wellcomeopenresearch.org/articles/9-64/v1
(全文テキスト(全般))

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)
公開されているフルテキストはありません
付随資料 (公開)
There is no public supplementary material available
引用

Roguski, A., Needham, N., MacGillivray, T., Martinovic, J., Dhillon, B., Riha, R., Armstrong, L., Campbell, I., Ferguson, A., Hilgen, G., Lako, M., Ritter, P., Santhi, N., von Schantz, M., & Spitschan, M. (2024). Investigating light sensitivity in bipolar disorder (HELIOS-BD). Wellcome Open Research, 9:. doi:10.12688/wellcomeopenres.20557.1.


引用: https://hdl.handle.net/21.11116/0000-000E-7390-D
要旨
Many people with bipolar disorder have disrupted circadian rhythms. This means that the timing of sleep and wake activities becomes out-of-sync with the standard 24-hour cycle. Circadian rhythms are strongly influenced by light levels and previous research suggests that people with bipolar disorder might have a heightened sensitivity to light, causing more circadian rhythm disruption, increasing the potential for triggering a mood switch into mania or depression.
Lithium has been in clinical use for over 70 years and is acknowledged to be the most effective long-term treatment for bipolar disorder. Lithium has many reported actions in the body but the precise mechanism of action in bipolar disorder remains an active area of research. Central to this project is recent evidence that lithium may work by stabilising circadian rhythms of mood, cognition and rest/activity. Our primary hypothesis is that people with bipolar disorder have some pathophysiological change at the level of the retina which makes them hypersensitive to the visual and non-visual effects of light, and therefore more susceptible to circadian rhythm dysfunction. We additionally hypothesise that the mood-stabilising medication lithium is effective in bipolar disorder because it reduces this hypersensitivity, making individuals less vulnerable to light-induced circadian disruption.
We will recruit 180 participants into the HELIOS-BD study. Over an 18-month period, we will assess visual and non-visual responses to light, as well as retinal microstructure, in people with bipolar disorder compared to healthy controls. Further, we will assess whether individuals with bipolar disorder who are being treated with lithium have less pronounced light responses and attenuated retinal changes compared to individuals with bipolar disorder not being treated with lithium. This study represents a comprehensive investigation of visual and non-visual light responses in a large bipolar disorder population, with great translational potential for patient stratification and treatment innovation.